Bilateral macular edema secondary to nab-paclitaxel therapy for breast cancer  

作　　者：Zi-Yi Zhou Ya-Ting Ye Jing-Ting Zhu Dong-Jie Sun Yu-Sheng Wang Guo-Rui Dou 

机构地区：[1]Department of Ophthalmology,Eye Institute of Chinese PLA,Xijing Hospital,Fourth Military Medical University,Xi’an 710032,Shaanxi Province,China [2]College of Life Sciences,Northwestern University,Xi’an 710032,Shaanxi Province,China

出　　处：《International Journal of Ophthalmology(English edition)》2024年第10期1963-1966,共4页国际眼科杂志（英文版）

基　　金：Supported by National Natural Science Foundation of China(No.81970814,No.82371071);Youth Science and Technology Nova Program of Shaanxi Province(No.2016KJXX-19);Xijing Supportive Grant(No.XJZT19ML19).

摘　　要：Dear Editor,Nanoparticle albumin bound(nab)–paclitaxel is a member of the taxane agents that has been proven efficient and widely applied in breast cancer as well as other kind of cancers.The taxane-induced macular edema has been recognized as an uncommon side effect which might regress after the drug withdraw.Here we presented our case as a rarely observed macular edema secondary to nab–paclitaxel therapy as follows.The consent from the patient was achieved and the research was approved by the Ethics Committee of Xijing Hospital(KY20202009-C-1).

关 键 词：EDEMA BREAST MACULAR 

分 类 号：R774.5[医药卫生—眼科]